There has been a huge focus on the safety and efficacy of both provision and monitoring of disease-modifying therapies for MS over the past few years, and with the dramatic increase in the variety and availability of the treatment it is unsurprising.

At the first MS Variance event we heard from neuropharmacist Rachel Dorsey-Campbell on her work to understand the true financial cost and human resource required to safely provide and monitor people receiving DMTs. This time, Professor Gavin Giovannoni listed the growing demand for DMTs and the expansion of the treatments to include primary-progressive MS, and potentially in the future secondary-progressive MS too, as one of the many reasons we must change our ways of working. 

Several posters examined their localities work in this area, and the poster on infectious complications was voted Runner-Up in the event’s poster competition.


Posted in:

Notify of
Inline feedbacks
View all comments